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Aneurysm-osteoarthritis syndrome (AOS) is an autosomal dominant
SMAD3 mutation that is characterized by aneurysms within the arterial
tree and early-onset arthritis of the joints (van der Linde et al., 2012; van
der Linde et al., 2013). It is uniquely different from Marfan's syndrome
(MFS) which is a disorder of the extracellular matrix, speciﬁcally
ﬁbrillin-1 (Judge and Dietz, 2005). In this issue of EBioMedicine, van
der Pluijm et al. dissect out the features of a whole body SMAD3 deﬁcient mouse and compares it to a Fibulin-4 deﬁcient mouse model (extracellular matrix defect model) (Fig. 8 of paper) (van der Pluijm et al.,
2016). It is extremely interesting that while the phenotypes in aneurysm formation are similar, the molecular mechanisms are quite distinct. The authors note that there were no changes in aortic stiffness
or MMP activity within the vascular smooth muscle cells (VSMCs) of
the SMAD3-deﬁcient mice, but instead more inﬂammatory inﬁltration
of immune cells into the adventitia. Likewise, while both models show
elevation of phosphorylated SMAD2 and ERK, the downstream targets
of TGF-β signaling are decreased with SMAD3 deﬁciency, but have no
effect or increased signaling with Fibulin-4 deﬁcient mice (van der
Pluijm et al., 2016).
Due to these differences in signaling, the authors suggest that blockade of inﬂammation may be a more appropriate treatment for those
with SMAD3 dysfunction. Another recent study has also concluded
that immune cells are dysfunctional with SMAD3 deﬁciency (Ye et al.,
2013). Currently, there are no drug therapies for the treatment of aneurysms and surgery is the only option. Those that have MFS are typically
placed on a beta-blocker, angiotensin converting enzyme inhibitor
(ACEi) or an angiotensin receptor blocker (ARB) (Judge and Dietz,
2005; Habashi et al., 2006). Interestingly, those patients that have mutations within the TGF-β receptors (Loeys-Dietz syndrome, LDS), such as
TGFBRI or TGFBRII, have elevated TGF-β signaling and may require medications that target this pathway or downstream targets (e.g. ERK),
however this is still highly controversial (Wheeler et al., 2014;
Akhurst and Hata, 2012; Cook et al., 2015). One of the problems with
DOI of original article: http://dx.doi.org/10.1016/j.ebiom.2016.09.006.
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targeting TGF-β is it has both canonical and non-canonical pathways.
The canonical pathway inﬂuences the phosphorylation of SMADs
which can modulate gene expression patterns at both pre- and posttranscription within the cell. This pathway typically inhibits the proliferation of cells, however under SMAD3 deﬁciency, VSMCs were
shown to have increased rates of proliferation (van der Pluijm et al.,
2016). This further indicates that patients with SMAD3 mutations may
not respond well to the current drug therapies that are used for MFS
and LDS patients, and it may require further testing to determine
what drug regiment might be best for this patient population.
AOS is also a recently identiﬁed aortic disease and is tied to familial
inheritance (Wheeler et al., 2014). It is important for families to be
screened for these mutations so that proper surveillance, via ultrasounds, can occur. Another interesting ﬁnding from the study by van
der Pluijm et al., was the difference in survival rates between males
and females with SMAD3 deﬁciency (van der Pluijm et al., 2016). Females tended to have better survival than males with SMAD3 deﬁciency, indicating that there may be gender differences. It has been well
documented that abdominal aortic aneurysms (AAAs) are sexually dimorphic in both mice and humans with males also being more susceptible to the disease (Henriques et al., 2004). It would be interesting to
see if this holds true in AOS patients as well.
This paper highlights the need for better understanding into the molecular signaling pathways that give rise to aneurysms. While under
SMAD3 deﬁciency, TGF-β signaling is disrupted, it may require different
types of drugs to help slow the progression of aneurysms in AOS patients. With the use of these novel mouse models, hopefully cardiovascular scientists will be able to bring new drugs and therapies to help
patients live better and more productive lives.
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